SBIR/STTR Research Award

DOMINANT PEPTIDE INHIBITORS OF PLANT VIRUS REPLICATION

Award identifier 80a941ce4d01c74b45dd5d8be1b0614316ceba1a84e962ec68b1c8f8bfcec4a1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,174

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DELTAGEN PROTEOMICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Verbatim from Applicant's Abstract):We have developed a technology for somatic cell genetics that leads rapidly to genetic agents that modulate cellular phenotypes. The technology utilizes genetic assays in combination with perturbagens, peptides that inhibit specific biochemical processes in cells, causing a phenotypic shift. Our perturbagen technology is potentially able to endow plants with novel phenotypes that would be very difficult to obtain by conventional plant breeding. The primary objective of the proposed research is to explore the use of perturbagen methods to identify peptide aptamers that confer resistance to the model viral pathogen tobacco etch virus (TEV), a member of the economically important potyviruses. Phase I research involves: (1)The identification of peptides that bind to TEV NIa and HC-Pro proteins and TEV RNA genome using the technology developed at Arcaris (specifically, perturbagen libraries) via modified yeast two-and three-hybrid systems. (2)The expression of these peptides in cultured tobacco cells to identify peptides that inhibit TEV replication. Protoplasts derived from these tobacco cells will be infected with transcripts of TEV that has been modified to include the b-glucuronidase (GUS) gene in its genome. The impact of these peptides on TEV replication will be monitored by GUS activity. PROPOSED COMMERCIAL APPLICATION: In contrast to viral sequence-derived resistance, perturbagen technology circumvents any potential risks associated with the expression of virus-derived transgenes. This approach has the potential to engineer highly durable virus resistance in plants by expression of peptides that interfere with the function several essential viral proteins. In addition, this technology can be used to rapidly identify perturbagens with fungicidal, bacteriocidal, and insecticidal properties that cna be expressed in plants.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.